Antidepressants

Psychedelic Wellness-Focused Company Delic to Acquire Ketamine Infusion Centers LLC

Retrieved on: 
Thursday, February 4, 2021
Drugs, Psychoactive drugs, Neurochemistry, Antidepressants, Amines, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Psychedelia, Psychedelic therapy, KIC

VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce it has entered into a binding letter agreement (the "Letter Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce it has entered into a binding letter agreement (the "Letter Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").
  • KIC will be Strategically Positioned to Leverage DELIC Platform and Brand: DELICexpectsto drive patients to KIC through its media platform and become a national leader
    Established History of Providing Ketamine Infusion Services.
  • By acquiring KIC, DELIC expands from being a central hub of psychedelic education, media, and information to being able to provide patients with psychedelic therapy.
  • DELIC was the first psychedelic umbrella platform and is currently a trusted source for those interested in psychedelic culture, psychedelic clinics, and more.

LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study of LB-102

Retrieved on: 
Tuesday, February 2, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Psychoactive drugs, Drugs, Receptor antagonists, Atypical antipsychotics, Pyrrolidines, Antidepressants, Amisulpride, Antiemetics, Dopamine, Positron emission tomography, Sulpiride, Management of schizophrenia, LB-102, LB Pharmaceuticals

This clinical study is designed to evaluate the dopamine receptor occupancy of LB-102 in healthy subjects using positron emission tomography (PET).

Key Points: 
  • This clinical study is designed to evaluate the dopamine receptor occupancy of LB-102 in healthy subjects using positron emission tomography (PET).
  • Amisulpride, which is not available in the US, is used for the treatment of schizophrenia and is widely prescribed in over 50 countries, including the EU.
  • The goal of this Phase 1b study is both to confirm dopamine target engagement and assist in dose selection for our upcoming Phase 2 study in acute schizophrenia patients.
  • A first-in-human, double-blind placebo-controlled Phase 1 study designed to test the safety and pharmacokinetics of LB-102 was completed over the summer of 2020.

Ketamine Taskforce for Access to Safe Care and Insurance Coverage Launches, Offering Hope to Chronic Pain and Mental Health Patients

Retrieved on: 
Monday, February 1, 2021
Data management, Insurance, Other Health, Technology, Law enforcement, Emergency services, Pharmaceutical, Professional services, Mental health, Medical devices, Public policy, Government, Other Technology, Science, Other Science, Health, Medical Supplies, Drugs, Psychoactive drugs, Branches of biology, Amines, Antidepressants, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Pain, Mental health

Today, the national Ketamine Taskforce for Access to Safe Care and Insurance Coverage has been launched.

Key Points: 
  • Today, the national Ketamine Taskforce for Access to Safe Care and Insurance Coverage has been launched.
  • The Taskforce has a mission to ensure access for pain and mental health patients to safe ketamine treatments through insurance coverage of the therapies.
  • This has left the tens of millions of Americans experiencing mental health conditions and pain with huge suffering and lack of access to affordable treatments.
  • In light of this heartbreaking reality, the Ketamine Taskforce was created to increase access to lifesaving ketamine treatments.

New report describes positive results of generic drug in treating COVID

Retrieved on: 
Monday, February 1, 2021
Selective serotonin reuptake inhibitors, Antidepressants, Health sciences, Occupational safety and health, Ethers, Fluvoxamine, Psychoactive drugs, Health, Coronavirus disease

"Repurposed drugs always have had the potential to be the fastest and least expensive way out of this pandemic.

Key Points: 
  • "Repurposed drugs always have had the potential to be the fastest and least expensive way out of this pandemic.
  • In this study, fluvoxamine was again shown to be 100% effective in the early treatment of COVID.''
  • In addition, after two weeks, none of the treatment group had any COVID symptoms while 60% of the group who declined the drug had one or more COVID symptoms.
  • CETF is funding a Phase 3 clinical trial to examine the efficacy of using fluvoxamine for the early treatment of COVID.

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine

Retrieved on: 
Monday, February 1, 2021
Drugs, Psychoactive drugs, Chemistry, Antidepressants, Amines, Dissociative drugs, Nicotinic antagonists, Sedatives, Microneedle, Ketamine, Esketamine, Hydrogel

PharmaTher will incorporate KETABET, its licensed patented formulation that combines FDA-approved ketamine and betaine, with Professor Donnellys patented hydrogel-forming microneedle (MN) patch technology.

Key Points: 
  • PharmaTher will incorporate KETABET, its licensed patented formulation that combines FDA-approved ketamine and betaine, with Professor Donnellys patented hydrogel-forming microneedle (MN) patch technology.
  • The proposed KETABET MN patch offers a potential game-changing therapeutic solution to treat mental health disorders, neurological and pain disorders.
  • Professor Ryan Donnelly commented: Our recent research with esketamine in our patented microneedle technology shows the potential of an alternative delivery method that can overcome the limitations of current ketamine delivery options without comprising the safety and compliance of patients.
  • He is a leading expert and researcher in the field of transdermal delivery with primary focus on microneedle drug delivery and its applications on improving therapeutic outcomes for patients.

Ketamine Media Launches KetaView Magazine to Further Its Mission to Raise Awareness About Treatment Options

Retrieved on: 
Friday, January 29, 2021
Psychoactive drugs, Drugs, Neurochemistry, Amines, Dissociative drugs, Antidepressants, Nicotinic antagonists, Ketones, Ketamine

KNOXVILLE, Tenn., Jan. 29, 2021 /PRNewswire/ -- Ketamine Media charts new territory in the field of ketamine treatment with the launch of KetaView Magazine, the industry's first dedicated publication.

Key Points: 
  • KNOXVILLE, Tenn., Jan. 29, 2021 /PRNewswire/ -- Ketamine Media charts new territory in the field of ketamine treatment with the launch of KetaView Magazine, the industry's first dedicated publication.
  • The first issue of KetaView is currently available to read in digital format across Ketamine Media's network of websites.
  • About Ketamine Media -In early 2016, Ketamine Media's parent company 360 Media worked with one of the nation's leading providers of ketamine infusion therapy across 8 states.
  • Since then, the team at Ketamine Media has worked tirelessly to design effective outreach tools and processes to help providers raise awareness about the clinical use of ketamine.

Champignon Brands' Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression

Retrieved on: 
Monday, January 25, 2021
Drugs, Psychoactive drugs, Neurochemistry, Antidepressants, Amines, Nicotinic antagonists, Ketones, Chloroarenes, Ketamine, Mental health, Management of depression, Major depressive disorder

This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel ketamine therapy treatment.

Key Points: 
  • This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel ketamine therapy treatment.
  • During the COVID-19 pandemic, the need for effective treatment has become exponentially critical," said Dr. Joshua Rosenblat, Medical Director, CRTCE.
  • "Ketamine treatment for depression is very difficult to access in Canada.
  • Champignon Brands Inc. ( https://champignonbrands.com ) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions.

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Retrieved on: 
Friday, January 8, 2021
Psychiatric diagnosis, Psychoactive drugs, Mood disorders, Drugs, Depression, Psychiatry, Antidepressants, Bipolar disorder, Major depressive disorder, Esketamine

KIELPIN, Poland, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Celon Pharma($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression.

Key Points: 
  • KIELPIN, Poland, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Celon Pharma($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression.
  • This was a randomized, double-blind, placebo-controlled, multi-center study of 88 adult patients with an inadequate response to at least two evidence-based treatment lines in bipolar depression.
  • We are extremely pleased with the robustness of the data from our Phase 2 trial, demonstrating that Falkieri shows real promise for patients with treatment-resistant bipolar depression, a highly debilitating condition with very few effective and approved therapeutic options.
  • This is highly important because majority of people with bipolar depression exhibit chronic and refractory course saidMaciej Wieczorek, PhD, Celon Pharma's CEO and Head of Research & Development.

Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Retrieved on: 
Thursday, December 31, 2020
Branches of biology, Dementia, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Biology, Psychiatry, Antidepressants, Bupropion/dextromethorphan, Alzheimer's disease, Agitation, Neurodegeneration

Initiation of the ACCORD Phase 3 trial in Alzheimers disease agitation continues the expedited clinical development of AXS-05 for this serious condition.

Key Points: 
  • Initiation of the ACCORD Phase 3 trial in Alzheimers disease agitation continues the expedited clinical development of AXS-05 for this serious condition.
  • Results of the meeting confirmed the pivotal status of the previously completed ADVANCE trial of AXS-05 in AD agitation.
  • ACCORD (Assessing Clinical Outcomes in Alzheimers Disease Agitation) is a Phase 3, randomized, double-blind, multicenter, placebo-controlled, trial to evaluate the efficacy and safety of AXS-05 in patients with Alzheimers disease (AD) agitation.
  • Alzheimers disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, and behavioral and psychological symptoms including agitation.

VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression

Retrieved on: 
Thursday, December 10, 2020
PH10, Antidepressants, Drugs, Medical research, Major depressive disorder, Health sciences, Pherine, NMDA receptor antagonists

With counterpart patents already issued in the U.S., Greater China, Europe and Japan, this patent enhances our patent protection for PH10 and is a key component of our global commercial protection strategy for PH10," stated Shawn K. Singh, Chief Executive Officer of VistaGen.

Key Points: 
  • With counterpart patents already issued in the U.S., Greater China, Europe and Japan, this patent enhances our patent protection for PH10 and is a key component of our global commercial protection strategy for PH10," stated Shawn K. Singh, Chief Executive Officer of VistaGen.
  • We believe PH10 has the potential to transform the treatment landscape for individuals with MDD in global depression markets, and we believe this patent will help protect and propel global development," continued Mr. Singh.
  • PH10 is an innovative odorless investigational synthetic neuroactive nasal spray designed to have rapid-onset and therapeutic potential in several neuropsychiatric indications involving depression, including MDD and suicidal ideation.
  • Following successfully completed exploratory Phase 2A clinical development, VistaGen is preparing for Phase 2B clinical development of PH10 as a potential stand-alone, rapid-onset treatment for MDD.